These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 29893791)

  • 1. Trastuzumab versus observation for HER2 nonamplified early breast cancer with circulating tumor cells (EORTC 90091-10093, BIG 1-12, Treat CTC): a randomized phase II trial.
    Ignatiadis M; Litière S; Rothe F; Riethdorf S; Proudhon C; Fehm T; Aalders K; Forstbauer H; Fasching PA; Brain E; Vuylsteke P; Guardiola E; Lorenz R; Pantel K; Tryfonidis K; Janni W; Piccart M; Sotiriou C; Rack B; Pierga JY
    Ann Oncol; 2018 Aug; 29(8):1777-1783. PubMed ID: 29893791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study‡.
    Conte P; Frassoldati A; Bisagni G; Brandes AA; Donadio M; Garrone O; Piacentini F; Cavanna L; Giotta F; Aieta M; Gebbia V; Molino A; Musolino A; Ferro A; Maltoni R; Danese S; Zamagni C; Rimanti A; Cagossi K; Russo A; Pronzato P; Giovanardi F; Moretti G; Lombardo L; Schirone A; Beano A; Amaducci L; Bajardi EA; Vicini R; Balduzzi S; D'Amico R; Guarneri V
    Ann Oncol; 2018 Dec; 29(12):2328-2333. PubMed ID: 30219886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial.
    Cameron D; Piccart-Gebhart MJ; Gelber RD; Procter M; Goldhirsch A; de Azambuja E; Castro G; Untch M; Smith I; Gianni L; Baselga J; Al-Sakaff N; Lauer S; McFadden E; Leyland-Jones B; Bell R; Dowsett M; Jackisch C;
    Lancet; 2017 Mar; 389(10075):1195-1205. PubMed ID: 28215665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Six versus 12 months' adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT.
    Earl H; Hiller L; Vallier AL; Loi S; McAdam K; Hughes-Davies L; Rea D; Howe D; Raynes K; Higgins HB; Wilcox M; Plummer C; Mahler-Araujo B; Provenzano E; Chhabra A; Gasson S; Balmer C; Abraham JE; Caldas C; Hall P; Shinkins B; McCabe C; Hulme C; Miles D; Wardley AM; Cameron DA; Dunn JA
    Health Technol Assess; 2020 Aug; 24(40):1-190. PubMed ID: 32880572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. One year versus a shorter duration of adjuvant trastuzumab for HER2-positive early breast cancer: a systematic review and meta-analysis.
    Inno A; Barni S; Ghidini A; Zaniboni A; Petrelli F
    Breast Cancer Res Treat; 2019 Jan; 173(2):247-254. PubMed ID: 30317424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Chan A; Delaloge S; Holmes FA; Moy B; Iwata H; Harvey VJ; Robert NJ; Silovski T; Gokmen E; von Minckwitz G; Ejlertsen B; Chia SKL; Mansi J; Barrios CH; Gnant M; Buyse M; Gore I; Smith J; Harker G; Masuda N; Petrakova K; Zotano AG; Iannotti N; Rodriguez G; Tassone P; Wong A; Bryce R; Ye Y; Yao B; Martin M;
    Lancet Oncol; 2016 Mar; 17(3):367-377. PubMed ID: 26874901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group.
    Wildiers H; Tryfonidis K; Dal Lago L; Vuylsteke P; Curigliano G; Waters S; Brouwers B; Altintas S; Touati N; Cardoso F; Brain E
    Lancet Oncol; 2018 Mar; 19(3):323-336. PubMed ID: 29433963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab.
    Pierga JY; Bidard FC; Autret A; Petit T; Andre F; Dalenc F; Levy C; Ferrero JM; Romieu G; Bonneterre J; Lerebours F; Bachelot T; Kerbrat P; Campone M; Eymard JC; Mouret-Reynier MA; Gligorov J; Hardy-Bessard AC; Lortholary A; Soulie P; Boher JM; Proudhon C; Charafe-Jaufret E; Lemonnier J; Bertucci F; Viens P
    Ann Oncol; 2017 Jan; 28(1):103-109. PubMed ID: 28177480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial.
    Earl HM; Hiller L; Vallier AL; Loi S; McAdam K; Hughes-Davies L; Harnett AN; Ah-See ML; Simcock R; Rea D; Raj S; Woodings P; Harries M; Howe D; Raynes K; Higgins HB; Wilcox M; Plummer C; Mansi J; Gounaris I; Mahler-Araujo B; Provenzano E; Chhabra A; Abraham JE; Caldas C; Hall PS; McCabe C; Hulme C; Miles D; Wardley AM; Cameron DA; Dunn JA;
    Lancet; 2019 Jun; 393(10191):2599-2612. PubMed ID: 31178152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Racial disparities in the rate of cardiotoxicity of HER2-targeted therapies among women with early breast cancer.
    Litvak A; Batukbhai B; Russell SD; Tsai HL; Rosner GL; Jeter SC; Armstrong D; Emens LA; Fetting J; Wolff AC; Silhy R; Stearns V; Connolly RM
    Cancer; 2018 May; 124(9):1904-1911. PubMed ID: 29381193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial.
    Pivot X; Romieu G; Debled M; Pierga JY; Kerbrat P; Bachelot T; Lortholary A; Espié M; Fumoleau P; Serin D; Jacquin JP; Jouannaud C; Rios M; Abadie-Lacourtoisie S; Venat-Bouvet L; Cany L; Catala S; Khayat D; Gambotti L; Pauporté I; Faure-Mercier C; Paget-Bailly S; Henriques J; Grouin JM;
    Lancet; 2019 Jun; 393(10191):2591-2598. PubMed ID: 31178155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients: extended follow-up of JBCRG-cohort study 01.
    Yamashiro H; Iwata H; Masuda N; Yamamoto N; Nishimura R; Ohtani S; Sato N; Takahashi M; Kamio T; Yamazaki K; Saito T; Kato M; Lee T; Kuroi K; Takano T; Yasuno S; Morita S; Ohno S; Toi M;
    Breast Cancer; 2020 Jul; 27(4):631-641. PubMed ID: 32060785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.
    Wagner AD; Grabsch HI; Mauer M; Marreaud S; Caballero C; Thuss-Patience P; Mueller L; Elme A; Moehler MH; Martens U; Kang YK; Rha SY; Cats A; Tokunaga M; Lordick F
    BMC Cancer; 2019 May; 19(1):494. PubMed ID: 31126258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial.
    Harbeck N; Huang CS; Hurvitz S; Yeh DC; Shao Z; Im SA; Jung KH; Shen K; Ro J; Jassem J; Zhang Q; Im YH; Wojtukiewicz M; Sun Q; Chen SC; Goeldner RG; Uttenreuther-Fischer M; Xu B; Piccart-Gebhart M;
    Lancet Oncol; 2016 Mar; 17(3):357-366. PubMed ID: 26822398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HER2-targeted therapy influences CTC status in metastatic breast cancer.
    Deutsch TM; Riethdorf S; Fremd C; Feisst M; Nees J; Fischer C; Hartkopf AD; Pantel K; Trumpp A; Schütz F; Schneeweiss A; Wallwiener M
    Breast Cancer Res Treat; 2020 Jul; 182(1):127-136. PubMed ID: 32436146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can estrogen receptor status predict for shorter duration of adjuvant trastuzumab in early-stage breast cancer?
    Mathew A; Erqou S
    Ann Oncol; 2018 Dec; 29(12):2391-2392. PubMed ID: 30357315
    [No Abstract]   [Full Text] [Related]  

  • 17. Adjuvant Chemotherapy and Trastuzumab Is Safe and Effective in Older Women With Small, Node-Negative, HER2-Positive Early-Stage Breast Cancer.
    Cadoo KA; Morris PG; Cowell EP; Patil S; Hudis CA; McArthur HL
    Clin Breast Cancer; 2016 Dec; 16(6):487-493. PubMed ID: 27622751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trastuzumab decreases the incidence of clinical relapses in patients with early breast cancer presenting chemotherapy-resistant CK-19mRNA-positive circulating tumor cells: results of a randomized phase II study.
    Georgoulias V; Bozionelou V; Agelaki S; Perraki M; Apostolaki S; Kallergi G; Kalbakis K; Xyrafas A; Mavroudis D
    Ann Oncol; 2012 Jul; 23(7):1744-50. PubMed ID: 22377561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of subcutaneous trastuzumab and intravenous trastuzumab as part of adjuvant therapy for HER2-positive early breast cancer: Final analysis of the randomised, two-cohort PrefHer study.
    Pivot X; Verma S; Fallowfield L; Müller V; Lichinitser M; Jenkins V; Sánchez Muñoz A; Machackova Z; Osborne S; Gligorov J;
    Eur J Cancer; 2017 Nov; 86():82-90. PubMed ID: 28963915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebrospinal fluid circulating tumor cells as a quantifiable measurement of leptomeningeal metastases in patients with HER2 positive cancer.
    Malani R; Fleisher M; Kumthekar P; Lin X; Omuro A; Groves MD; Lin NU; Melisko M; Lassman AB; Jeyapalan S; Seidman A; Skakodub A; Boire A; DeAngelis LM; Rosenblum M; Raizer J; Pentsova E
    J Neurooncol; 2020 Jul; 148(3):599-606. PubMed ID: 32506369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.